ATTO Attovia Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2058707 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3.4%
Debt / equity0.00x
Current ratio34.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0 | $450,000 | — | $360,000 | $0 | — |
| R&D expense | $20.29M | $18.95M | — | $12.32M | $13.59M | — |
| SG&A expense | $4.73M | $3.31M | — | $3.65M | $3.03M | — |
| Operating income | -$25.02M | -$21.80M | — | -$15.60M | -$16.62M | — |
| Net income | -$22.27M | -$20.69M | -$18.66M | -$13.78M | -$14.44M | -$15.15M |
| EBITDA | -$24.82M | -$21.60M | — | -$15.40M | -$16.42M | — |
| EPS (basic) | -0.76 | -4.88 | — | -3.44 | -3.71 | — |
| EPS (diluted) | -0.76 | -4.88 | — | -3.44 | -3.71 | — |
| Weighted avg. shares (diluted) | 29.37M | 4.24M | — | 4.00M | 3.90M | — |
| Balance sheet | ||||||
| Cash & equivalents | $115.37M | $32.83M | — | $49.77M | $42.65M | — |
| Short-term investments | $280.57M | $82.30M | — | — | — | — |
| Current assets | $404.52M | $118.40M | — | — | — | — |
| PP&E, net | $3.15M | $3.34M | — | — | — | — |
| Total assets | $411.82M | $128.35M | — | — | — | — |
| Current liabilities | $11.67M | $12.62M | — | — | — | — |
| Total liabilities | $14.08M | $15.58M | — | — | — | — |
| Shareholders' equity | $397.74M | -$145.46M | -$125.52M | -$90.92M | -$75.53M | -$61.76M |
| Shares outstanding | 45.68M | 4.53M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$25.67M | — | — | -$15.16M | — | — |
| Capital expenditure | $17,000 | — | — | $375,000 | — | — |
| Free cash flow | -$25.69M | — | — | -$15.53M | — | — |
| Investing cash flow | -$199.75M | — | — | $22.27M | — | — |
| Financing cash flow | $307.96M | — | — | $13,000 | — | — |
| Depreciation & amortization | $200,000 | $200,000 | — | $200,000 | $200,000 | — |
| Stock-based compensation | $1.63M | $692,000 | — | $679,000 | $563,000 | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.